Date: 2015-09-28
Type of information: Nomination
Compound:
Company: ADC Therapeutics (Switzerland)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details: * On September 28, 2015, ADC Therapeutics, an oncology drug development company focused on Antibody Drug Conjugates (ADCs) targeting major cancers, announced that Dr Hans-Peter Wild and Jacques Theurillat have been appointed to its Board of Directors as Non-Executive Directors. The appointments follow ADCT’s recent $80m financing and further strengthens ADCT’s board as it matures as a Company. Dr Wild is the owner and Chairman of the Wild Group and has built multiple global businesses, including Wild Flavours GmbH; one of the world’s leading producers and suppliers of natural ingredients for the food and drink industry, a global consumer goods business under the CapriSun® brand, and a processing units manufacturer for the food and drink industry. Dr Wild has an Honours degree in Law from the University of Heidelberg and gained his doctorate from the Faculty of Law at the University of Mannheim. He also holds a Master in Business Administration from the University of Mannheim and is an Honorary Senator of the University of Heidelberg. As an independent Non Executive Director, Jacques Theurillat brings to the Board extensive experience in strategy development, finance and commercial operations. He has been CEO of Ares Life Sciences AG and previously served as CEO and Chairman of Albea Pharmaceuticals AG. He also had an extensive career at Serono, which spanned roles such as Chief Financial Officer, Deputy Chief Executive Officer and Senior Executive Vice President, Strategic Corporate Development. Mr Theurillat holds Bachelor of Law Degrees from Madrid University and Geneva University, a Master’s Degree in Finance from Centro Estudios Financieros, Madrid and a Swiss Federal Tax Expert Diploma. The other members of the Board of ADC Therapeutics are: Dr. Peter B. Corr (Chairman), Stephen Evans-Freke, Michael Forer (Messrs. Corr, Evans-Freke, and Forer of founding investor Auven Therapeutics), Dr Bahija Jallal (Executive Vice President of AstraZeneca and head of MedImmune), and independent Non-Executive Director Dr Barrie Ward (former CEO of Kudos).
Financial terms:
Latest news:
